dimanche 15 novembre 2026
RechercherExplore
fr.via.news
Source trace. Via News points to the documents behind its reporting and shows what we drew from each, so you can check any claim. How we source
Source document· January 16, 2026

Smart Home Healthcare Market Outlook 2025-2033: Analysis of Growth Drivers, Constraints, Opportunities, and Trends | Astute Analytica

View original at globenewswire.com
Smart Home Healthcare Market Outlook 2025-2033: Analysis of Growth Drivers, Constraints, Opportunities, and Trends | Astute Analytica Chicago, Jan…
Opening lines of the source · short snapshot: read the full document at the original

Ce que nous avons tiré de cette source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • The global smart home healthcare market was valued at US$ 27.46 billion in 2024 and is estimated to surpass a market size of US$ 194.51 billion by 2033 at a CAGR of 24.3% during the forecast period 2025–2033

    80% confidence

  • Testing, screening, and monitoring products captured a commanding 76.90% share of revenue in the smart home healthcare market in 2024

    80% confidence

  • The growth of the smart home healthcare market is strongly influenced by the increasing number of aging individuals who prioritize maintaining independence while managing their health

    80% confidence

  • Approximately 48.9 million households in the United States currently utilize at least one connected health device

    80% confidence

  • The growing prevalence of chronic diseases is a major catalyst driving the expansion of the smart home healthcare market

    80% confidence

  • Global shipment volume of wearable health devices reached 487 million in 2024

    80% confidence
Ce que nous savons · l'intelligence derrière cette page
En direct du substrat
Ce que nous observons
Q4 2026 Biotech Catalyst Cluster: Late-Stage Data and PDUFA Dates Converge
Early-to-mid November 2026 is a dense run of clinical readouts and Q3 earnings at AHA, AASLD, ACR and ASH. Mid-cap biotechs (Vir, Mineralys, Arrowhead, Oryzon, Novartis, J&J) are reporting data that feeds into regulatory decisions. The next ones are the ivonescimab BLA (Nov 14) and the lorundrostat PDUFA (Dec 22), followed by ECLIPSE 2/3 and Maritime-1 readouts in Q1 2027. The list also includes an unrelated delisting track (EGM Nov 19, application Jan 25, 2027), and the facts have no AI or fintech content.
Notre lecture des données ›
Signaux que nous suivons
Satellite-Terrestrial Network Integration Acceleration
Increased investment and launches in hybrid satellite-cellular networks across telecom industry; competitive responses from other carriers; regulatory activity around satellite spectrum; expansion of emergency/rural connectivity use cases
Tendances que nous surveillons ›
Là où les sources divergent
Sources réconciliées : aucun conflit ouvert pour l'instant.
Nous signalons les conflits ouvertement ›
Vérifié récemment
✓ Vérifié avec la source d'origine
4,959
faits reliés à leur source, et nous signalons ceux qui ne tiennent pas.
101 entités suivies4,959 faits vérifiés avec la source5,585 documents sources archivés
Interrogez ces données → isubstrate.com
Smart Home Healthcare Market Outlook 2025-2033: Analysis of Growth Drivers, Constraints, Opportunities, and Trends | Astute Analytica: Source | Via News | fr.via.news